During the last session, PhenomeX Inc. (NASDAQ:CELL)’s traded shares were 1.05 million. At the end of the trading day, the stock’s price was $0.70, reflecting an intraday loss of -6.48% or -$0.05. The 52-week high for the CELL share is $6.11, that puts it down -772.86 from that peak though still a striking -5.71% loss since the share price plummeted to a 52-week low of $0.74. The company’s market capitalization is $68.22M, and the average intraday trading volume over the past 10 days was 0.64 million shares, and the average trade volume was 621.07K shares over the past three months.
PhenomeX Inc. (CELL) received a consensus recommendation of a Hold from analysts. That translates to a mean rating of 2.90. CELL has a Sell rating from 1 analyst(s) out of 7 analysts who have looked at this stock. 4 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.3.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
PhenomeX Inc. (NASDAQ:CELL) trade information
PhenomeX Inc. (CELL) registered a -6.48% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.48% in intraday trading to $0.70 this Thursday, 05/25/23, hitting a weekly high. The stock’s 5-day price performance is -15.50%, and it has moved by -38.20% in 30 days. Based on these gigs, the overall price performance for the year is -83.80%. The short interest in PhenomeX Inc. (NASDAQ:CELL) is 3.49 million shares and it means that shorts have 8.03 day(s) to cover.
The consensus price target of analysts on Wall Street is $5.67, which implies an increase of 87.65% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3.00 and $9.00 respectively. As a result, CELL is trading at a discount of -1185.71% off the target high and -328.57% off the low.
PhenomeX Inc. (CELL) estimates and forecasts
Statistics show that PhenomeX Inc. has outperformed its competitors in share price, compared to the industry in which it operates. PhenomeX Inc. (CELL) shares have gone down -74.84% during the last six months, with a year-to-date growth rate more than the industry average at 23.19% against 11.40. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to grow 21.10% this quarter and then jump 18.80% in the quarter after that. In the rating firms’ projections, revenue will increase 2.50% compared to the previous financial year.
Revenue for the current quarter is expected to be $17.68 million as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to $20.85 million by the end of Sep 2023. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $19.15 million and $21.4 million respectively. In this case, analysts expect current quarter sales to shrink by -7.70% and then drop by -2.60% in the coming quarter.
While earnings are projected to return -32.40% in 2023.
PhenomeX Inc. is due to release its next quarterly earnings between August 07 and August 11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
PhenomeX Inc. (NASDAQ:CELL)’s Major holders
PhenomeX Inc. insiders own 11.05% of total outstanding shares while institutional holders control 55.88%, with the float percentage being 62.83%. Northpond Ventures, Llc is the largest shareholder of the company, while 165 institutions own stock in it. As of Mar 30, 2023, the company held over 5.39 million shares (or 5.46% of all shares), a total value of $6.25 million in shares.
The next largest institutional holding, with 4.84 million shares, is of Blackrock Inc.’s that is approximately 4.89% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $5.61 million.
Also, the Mutual Funds coming in first place with the largest holdings of PhenomeX Inc. (CELL) shares are ARK ETF Tr-ARK Genomic Revolution ETF and Vanguard Total Stock Market Index Fund. Data provided on Mar 30, 2023 indicates that ARK ETF Tr-ARK Genomic Revolution ETF owns about 2.28 million shares. This amounts to just over 2.31 percent of the company’s overall shares, with a $2.65 million market value. The same data shows that the other fund manager holds slightly less at 2.06 million, or about 2.08% of the stock, which is worth about $5.51 million.